Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 8:05 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 125 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Dexamethasone IV injection Clear all

Conditions: Nausea and Vomiting, Postoperative
Interventions: Amisulpride Injection, Dexamethasone; Drug
Lead sponsor: Acacia Pharma Ltd; Industry
Eligibility: 2 Months to 17 Years
Enrollment: 453 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 5
States / cities: Sheffield, Alabama • Atlanta, Georgia • Minneapolis, Minnesota + 2 more

Conditions: Multiple Myeloma
Interventions: Carfilzomib 20 mg/m^2, Carfilzomib 70 mg/m^2, Dexamethasone 40 mg, Dara-SC 1800 mg, Dexamethasone 20 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 11
States / cities: Gilbert, Arizona • Tucson, Arizona • Whittier, California + 8 more

Conditions: Multiple Myeloma
Interventions: Carfilzomib, Bortezomib, Dexamethasone; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 929 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 27
States / cities: Burbank, California • La Jolla, California • Los Angeles, California + 22 more

Conditions: Recurrent Medulloblastoma, Recurrent Ependymoma
Interventions: Irinotecan, Temozolomide, Bevacizumab, Omburtamab I-131, Liothyronine, SSKI, Dexamethasone, Antipyretic, Antihistamine, anti-emetics; Drug
Lead sponsor: Pediatric Brain Tumor Consortium; Network
Eligibility: Up to 21 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 3
States / cities: Los Angeles, California • New York, New York • Cincinnati, Ohio

Conditions: Multiple Myeloma
Interventions: myPRS, Induction 1 - MEL-10+CFZ-TD-PACE, First Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic), Inter-Therapy - MEL-20+CFZ-TD-PACE (75%), Second Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic), Consolidation - CFZ-TD-PACE, Maintenance - CFZ-R(T)-D; Device · Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia
Interventions: Decitabine, Dexamethasone, Palbociclib, Sorafenib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 15 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Readiness to Discharge
Interventions: Peri-Articular Injection, Epidural Pathway (PCEA+FNB); Procedure
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 85 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Light Chain Deposition Disease (LCDD or MIDD), Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD), Monoclonal Immunoglobulin Deposition Disease (MIDD), Amyloidosis
Interventions: Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 2 more

Conditions: Multiple Myeloma
Interventions: Carfilzomib, Cyclophosphamide, Dexamethasone; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 9
States / cities: Encinitas, California • West Hollywood, California • Whittier, California + 6 more

Conditions: Plasma Cell Myeloma
Interventions: Isatuximab intravenous (IV), Cemiplimab (SAR439684), Dexamethasone, Lenalidomide, Pomalidomide, Isatuximab subcutaneous (SC), Carfilzomib; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Multiple Myeloma
Interventions: Eftozanermin alfa, Bortezomib, Dexamethasone; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 5
States / cities: Atlanta, Georgia • Louisville, Kentucky • Boston, Massachusetts + 2 more

Conditions: Post Operative Pain, Acute, Periodontitis
Interventions: Dexamethasone IV injection, Dexamethasone Capsule, Placebo IV administration, Placebo capsule; Drug · Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Multiple Myeloma
Interventions: Etentamig, Lenalidomide, Daratumumab, Dexamethasone; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 680 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2042
U.S. locations: 17
States / cities: Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 12 more

Conditions: Amyloidosis
Interventions: GSK2315698 (CPHPC), GSK2398852 (anti-SAP mAb); Drug · Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Acute Lymphoblastic Leukemia
Interventions: Bortezomib, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, Methotrexate, Vincristine, Triple IT Therapy; Drug
Lead sponsor: Therapeutic Advances in Childhood Leukemia Consortium; Other
Eligibility: 1 Year to 21 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 20
States / cities: Duarte, California • Long Beach, California • Los Angeles, California + 16 more

Conditions: Covid19
Interventions: IFN beta-1a, Dexamethasone; Drug
Lead sponsor: Faron Pharmaceuticals Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: Aurora, Colorado • Boston, Massachusetts • Newton, Massachusetts + 1 more

Conditions: Multiple Myeloma
Interventions: Elotuzumab, Dexamethasone, Lenalidomide, Bortezomib, Pomalidomide, Nivolumab; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 14
States / cities: Tucson, Arizona • Bakersfield, California • Fountain Valley, California + 11 more

Conditions: Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
Interventions: Ponatinib, Imatinib, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 15
States / cities: Birmingham, Alabama • Duarte, California • Los Angeles, California + 11 more

Conditions: Plasma Cell Myeloma Refractory
Interventions: Isatuximab, Dexamethasone, Pomalidomide, Belantamab mafodotin, Pegenzileukin, SAR439459, Belumosudil, Evorpacept; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 5
States / cities: Atlanta, Georgia • Chicago, Illinois • Ann Arbor, Michigan + 2 more

Conditions: Acute Lymphoblastic Leukemia, ALL, Childhood, ALL
Interventions: Ruxolitinib, Cyclophosphamide, Cytarabine, Mercaptopurine, Vincristine, Pegaspargase, Rituximab, Methotrexate (Intrathecal Administration), Methotrexate (Intravenous Administration), Dexamethasone, Doxorubicin, Thioguanine, Methotrexate Oral Product; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 39 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 2
States / cities: Chicago, Illinois • Dallas, Texas

Conditions: Multiple Myeloma
Interventions: Etentamig, Carfilzomib, Pomalidomide, Elotuzumab, Selinexor, Bortezomib, Dexamethasone; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 421 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 46
States / cities: Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 37 more

Conditions: Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM), Autologous Stem Cell Transplant
Interventions: Isatuximab, Lenalidomide, Bortezomib Injection, Dexamethasone; Drug
Lead sponsor: Jacob Laubach, MD; Other
Eligibility: 75 Years and older
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pain
Interventions: Ropivacaine, dex, Bupivacaine, Saline; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 2
States / cities: Cleveland, Ohio • Euclid, Ohio

Conditions: Postoperative Pain
Interventions: Continuous Erector Spinae Plane Nerve Block, Continuous Quadratus Lumborum Nerve Block, Single Erector Spinae Plane Nerve Block, Single Quadratus Lumborum Nerve Block, Lidocaine IV, Ropivacaine 0.5% Injectable Solution, Dexamethasone, Dexmedetomidine, Lidocaine; Procedure · Drug
Lead sponsor: Jeremy Kearns; Other
Eligibility: 18 Years to 90 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Search by objective public record fields.

Study of Intravenous Amisulpride for Prophylaxis of Post-operative Nausea and Vomiting (PONV) in Pediatric Patients

Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab

Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia

Analgesia After Total Knee Arthroplasty: Peri-Articular Injection Versus Epidural + Femoral Nerve Blockade

Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis

A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma

The Effect of Dexamethasone on Short Term Patient Response: IV vs Oral Administration

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Multiple Treatment Session Study to Assess GSK2398852 Administered Following and Along With GSK2315698

Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)

Human Intravenous Interferon Beta-Ia Safety and Preliminary Efficacy in Hospitalized Subjects With COVID-19

Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab

A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM

Interscalene Nerve Blocks With Ropivacaine Alone, With Dexamethasone, Plus Systemic Dexamethasone

Continuous Nerve Block Block vs Combination of Single Block Plus Intravenous Lidocaine for Postoperative Pain.